STAT

The data are in, but debate rages: Are hospital readmission penalties a good idea?

"The worst-case scenario" or a resounding success? Experts can't agree on what the numbers show.
Source: Evan Vucci/AP

A closely watched experiment in health care has unfolded over the last few years: Financial incentives for hospitals to reduce readmissions. It was a feature of the Affordable Care Act, and researchers are now assessing its impacts. But even as data have arrived, an impassioned argument has broken out among experts — looking at the same numbers, they have reached different conclusions about whether the policy is making Americans healthier.

And, underscoring that disagreement is a deeper one — about what kind of evidence is needed before a health policy is enacted on a national scale.

The policy, known as the , created financial penalties for hospitals whose readmissions exceed the national average for patients suffering from heart failure, heart attacks, and pneumonia. In recent years it has been expanded to include other conditions. Its aim was to encourage

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Ozempic And An Eye Condition, A Failed Roche Cancer Drug Trial, And More
A study reported for the first time a potential link between Novo Nordisk's GLP-1 drugs and an eye condition that can cause vision loss.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Probing Teva Patents, A Moderna Flu Vaccine Contract, And More
The FTC is investigating Teva Pharmaceuticals after it refused to remove about two dozen patents for asthma and COPD inhalers from a federal registry.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Merck Pneumococcal Shot, Kansas Suing Pfizer, And More
In today's Pharmalittle roundup, we're reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more.

Related Books & Audiobooks